Introduced by Smith+Nephew in the US during 2024, the CARTIHEAL Implant is rapidly transforming the cartilage repair ...
ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target. Cancer ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient ou ...
Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized ...
EDINBURGH, Scotland-- (BUSINESS WIRE)--RoslinCT, a leading global cell therapy Contract Development and Manufacturing ...
Additionally, Thermo Fisher is expanding small molecule capabilities through its collaboration with AustinPx, giving ...
Financing will advance a potential once-daily oral treatment designed to restore blood vessel stability in HHT, a serious inherited bleeding disorder with no approved therapies. periSCOPE platform ...
The new microbiology lab solidifies PPS' position as a leader in sterile injectables, empowering Lexington to deliver high ...
The financing marks an important milestone for Rewind as it advances its lead GPR17 antagonist program toward the clinic. The ...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral ...
UPPSALA, SE / ACCESS Newswire / October 5, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - "We reaffirm our target of reaching ...
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET. Orion Pharma announces first patient dosed in Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results